Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib

By T. Mashiba, T. Hirano, C. Turner, M. Forwood, C. Johnston, D. Burr. Journal of Bone and Mineral Research, 2000

725 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research (2010, background): “Since only 6 women in the subset with pelvic radiographs had taken BPs, more data are required on the role of cortical thickness in atypical femoral fractures in BP users.”
Denosumab and bisphosphonates: different mechanisms of action and effects. (2011, methodology): “Studies using a beagle dog model have shown that long-term suppression of bone turnover by bisphosphonates is associated with microdamage accumulation in the ribs and vertebrae [137–140].”
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate (2003, background): “associated with accumulation of mirocracks and a decrease in the toughness of bone.((23)) However, no threshold could be identified for nonvertebral fractures.”
Severely suppressed bone turnover: a potential complication of alendronate therapy. (2005, background): “Group A 1 55/F PO 6 Ca, D Sacrum (6) NA No (12) 2 76/F PO 7 Ca, D Vertebra, rib (7) NA Yes (6) 3 52/F POpen 8 Ca, D Femoral shaft (8) 4 months (femoral shaft) No (9)”